Atranorin
APC-753
Atranorin
Cat. No.
APC-753
CAS No.
479-20-9
MF
C19H18O8
MW
374.34142
Atranorin is a secondary metabolite of lichens and an AKT inhibitor.
Need help? Our team of experienced experts is here for you with full support.
Technical Data
Description
Storage and Shipping
References
Product Name
CAS No.
479-20-9
MF
C19H18O8
MW
374.34142
Specification
98%
Research Area
Antibacterial, anti-inflammatory, and antioxidant
Description
Atranorin is a secondary metabolite of lichens and an AKT inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g Availability: In stock
Storage and Shipping
Store under frozen or refrigerated conditions, keep away from strong light and heat.
References
[1]. Melo MG, et al. Redox properties and cytoprotective actions of atranorin, a lichen secondary metabolite. Toxicol In Vitro. 2011 Mar;25(2):462-8.
[2]. Semenov K N, et al. Atranorin is a novel potential candidate drug for treating myelodysplastic syndrome. Journal of Molecular Liquids, 2024, 413: 125743.
[3]. Zhou R, et al. The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis. Sci Rep. 2017 Aug 15;7(1):8136.
[4]. Barreto R S S, et al. Evaluation of wound healing activity of atranorin, a lichen secondary metabolite, on rodents. Revista Brasileira de Farmacognosia, 2013, 23(2): 310-319.
[5]. Ranković B, et al. The antimicrobial activity of substances derived from the lichens Physcia aipolia, Umbilicaria polyphylla, Parmelia caperata and Hypogymnia physodes. World journal of microbiology and biotechnology, 2008, 24: 1239-1242.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.